DrugPatentWatch Database Preview
ACTEMRA Drug Profile
Summary for Tradename: ACTEMRA
| Patents: | 59 |
| Applicants: | 1 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ACTEMRA |
Pharmacology for ACTEMRA
| Mechanism of Action | Interleukin 6 Receptor Antagonists |
US Patents for ACTEMRA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | See Pricing | LegoChem Biosciences, Inc. (Daejeon, KR) | 2034-05-28 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | See Pricing | LegoChem Biosciences, Inc. (Daejeon, KR) | 2034-05-28 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | See Pricing | Celgene Corporation (Summit, NJ) | 2033-03-14 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | See Pricing | University of Maryland, Baltimore (Baltimore, MA) | 2031-03-03 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ACTEMRA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5231231 | See Pricing |
| Russian Federation | 2013126477 | See Pricing |
| Brazil | PI0406574 | See Pricing |
| European Patent Office | 1543839 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
